This article discusses how the concentration of specific metabolites in urine, such as 3HPMA, can serve as indicators of health risks associated with smoking tobacco. It also examines how these biomarkers can be used to evaluate the effects of transitioning from traditional smoking to nicotine vaping.
Understanding these biomarkers helps in assessing exposure levels and health implications, supporting public health efforts to reduce smoking-related diseases and promote safer alternatives.